Non-inferiority Bioavailabilty Study of 3 Silicon-rich Supplements
NCT ID: NCT03108508
Last Updated: 2020-07-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
5 participants
INTERVENTIONAL
2017-05-01
2017-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bioavailability of Different Collagen-based Treatments After Oral Intake
NCT05722158
Bioavailability of Astaxanthin Formulations
NCT03443882
To Evaluate the Efficacy of a Nutraceutical in Reducing Cardiovascular Risk in Healthy Subjects
NCT04506749
Evaluate the Effectiveness and Safety of the Alpinia Galanga Formulation, Theacrine Formulation, and Caffeine Formulation on Fatigue, Mental Acuity, and Cognitive Health
NCT05170113
Study of a Nutritional Supplement for Healthy Aging
NCT06743841
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants: 5 healthy men over 18 years old, with normal serum creatinine levels. Treatment consists of one product consumption every week, and measuring postprandrial response at 0, 30, 60, 90, 120, 180, 240 and 360 min, in blood, and urine in two periods of three hours each.
The statistical analysis will follow the principles specified in the guidelines of the ICHE and CPMP/EWP/908/99 ICHE Points to Consider on Multiplicity Issues in Clinical Trials.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prod1
G5 Siliplant
Prod1
60 mL of product (water, silicic acid, Equisetum Arvense, Rosmarinus officinalis) (Silicic acid) equivalent to 21.6 mg of elemental silicon.
Prod2
Orgono Powder®
Prod2
1.4 g of product (Orthosalicic acid) equivalent to 21.6 mg of elemental silicon
Prod3
G7 ALOE
Prod3
120 mL of product (Aloe barbadensis Miller, organic silicon, potassium sorbate, cítric acid) (Organic silicon) equivalent to 21.6 mg of elemental silicon
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prod1
60 mL of product (water, silicic acid, Equisetum Arvense, Rosmarinus officinalis) (Silicic acid) equivalent to 21.6 mg of elemental silicon.
Prod2
1.4 g of product (Orthosalicic acid) equivalent to 21.6 mg of elemental silicon
Prod3
120 mL of product (Aloe barbadensis Miller, organic silicon, potassium sorbate, cítric acid) (Organic silicon) equivalent to 21.6 mg of elemental silicon
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* With normal serum creatinine levels.
* Written informed consent provided before the initial screening visit.
Exclusion Criteria
* Suffering from intestinal disorders
* Consuming silicon supplements in the 7 days prior to inclusion in the study.
* Consuming medicines containing silicon in the 7 days prior to inclusion in the study.
* Current or past participation in a clinical trial or consumption of a research product in the 30 days prior to inclusion in the study.
* Failing to follow study guidelines.
18 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SILICIUM ESPAÑA LABORATORIOS SLU
UNKNOWN
Hospital Universitari Sant Joan de Reus
OTHER
University Rovira i Virgili
OTHER
Technological Centre of Nutrition and Health, Spain
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Technological Centre of Nutrition and Health (CTNS)
Reus, Tarragona, Spain
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Technological Centre of Nutrition and Health
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BIOSILICI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.